

INTERIM FORMULARY UPDATE

The following recommendations, made at the February 15, 2008 meeting of the Executive Formulary Committee, are approved:

Dosage strength/formulations **recommended to be deleted** from to the DADS/DSHS Drug Formulary based on the Sectional Reviews for Dermatological Agents, Part II and the SSRI Review:

Generic Name	Brand Name	Dosage forms to be deleted	Dosage forms still available
Aluminum acetate	Burow's Solution	Solution, topical: 480 ml	None
Bupivacaine	Marcaine®	Injection: 0.25%, 0.5%, 0.75%	None
Crotamiton	Eurax®	Lotion: 10%	None
Lindane	Kwell®	Lotion: 1% Shampoo: 1%	None
Imipramine pamoate	Tofranil-PM®	Capsule: 75 mg, 100 mg, 125 mg, 150 mg	Tablet: 10 mg, 25 mg, 50 mg (as hydrochloride)
Protriptyline	Vivactil®	Tablet: 5 mg, 10 mg	None

Feedback will be obtained from the field regarding the proposed deletions.

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on New Drug Applications:

Generic Name	Brand Name	Dosage Form	Classification
Fenofibrate		Tablet: 54 mg, 160 mg	Cardiovascular: Antihyperlipidemics
Ibandronate	Boniva®	Tablet: 2.5 mg, 150 mg,	Endocrine Agents: Miscellaneous

Product(s) **tableted for addition** to the DADS/DSHS Drug Formulary based on New Drug Applications:

Generic Name	Brand Name	Dosage Form	Classification
Omega-3-acid ethyl esters	Lovaza®	Capsule: 1 g	Cardiovascular: Antihyperlipidemics

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on the Sectional Reviews for Dermatological Agents, Part II and the SSRI Review:

Generic Name	Brand Name	Dosage Form	Classification
Papain-Urea	Accuzyme®, Ethezyme®, Kovia®	Ointment	Dermatological Agent: Wound Agent
	Gladase-C®, Panafil®	Ointment with chlorophyllin	Dermatological Agent: Wound Agent
Wound Cleanser	CarraKlenz®	Spray	Dermatological Agent: Wound Cleanser

Dosage strength(s) **recommended to be added** to the DADS/DSHS Drug Formulary based on the Sectional Reviews for Dermatological Agents, Part II and the SSRI Review:

Generic Name	Brand Name	Dosage Form	Classification
Clobetasol	Temovate	Lotion: 0.05% Shampoo: 0.05%	Dermatological Agent: Corticosteroids
Coal Tar		Cream: 2%	Dermatological Agent: Tar Containing Agents
Trypsin/balsam Peru/caster oil	Allander-T®, Xenaderm,	Ointment	Dermatological Agent: Miscellaneous

Other recommendations:

- Add specific allele monitoring for patients with Asian descent to the carbamazepine audit criteria and guidelines
- For the Medication Audit Criteria
 - Remove Nefazodone (Serzone®) audit criteria as it is no longer a formulary antidepressant agent
 - Remove the separate clomipramine (Anafranil®) audit criteria and merge with other TCA audit criteria
 - Merge venlafaxine (Effexor®, Effexor® XR) with duloxetine (Cymbalta®) and title SNRIs
 - Specific changes to the following Audit Criteria: amoxapine (Asendin®); bupropion (Wellbutrin®, Wellbutrin SR®); Monoamine Oxidase Inhibitors; trazodone (Desyrel®); Tricyclic Antidepressants

Other **recommendation(s)/addition(s)/revisions(s)** to the DADS/DSHS Drug Formulary:

1. Remove Pertofrane® as a trade name for desipramine and Adapin® as trade name for doxepin
2. Add Budeprion® as a trade name for bupropion and add Remeron® SolTab as a trade name for mirtazapine
3. Remove “for obsessive-compulsive disorder” for the clomipramine entry
4. Remove imipramine pamoate capsules from the Formulary
5. Delete protriptyline (Vivactil®) from the Formulary
6. Create a Wound Agents section and include:
 - Collagenase (Santyl®)
 - Papain/urea
 - Trypsin/balsam Peru/caster oil (Granulex®)
 - Wound cleanser
7. Add the following trade names (-T®, Granul-Derm®, TBC®, Xenaderm®) to Trypsin/balsam Peru/caster oil

For the Maximum Dosing Table for Antidepressants

8. Add amitriptyline therapeutic concentration = 120-250 ng/ml (parent drug plus metabolite)
9. Add doxepin therapeutic concentration = 150 ng/ml (parent drug plus metabolite) and remove Adapin® as a brand name product
10. After desipramine therapeutic concentration add “(parent drug plus metabolite)”
11. Add clomipramine to Antidepressant Maximum Table and remove it from the Miscellaneous Table

APPROVED:



Pharmacy Director, San Antonio State Hospital